Navigation Links
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
Date:11/1/2008

doses 12 hours apart, the concentration of ANA598 in plasma 12 hours after the second dose was 83 ug/mL, which substantially exceeds the level predicted to display antiviral potency. The data will be presented in a late-breaker poster titled "Results of a Phase I Safety, Tolerability and Pharmacokinetic Study of ANA598, a Non-Nucleoside NS5B Polymerase Inhibitor, in Healthy Volunteers", at 1:00 p.m. PST on Monday, November 3.

ANA598 Preclinical Data at AASLD Meeting

In addition to the results of the Phase I healthy volunteer study, Anadys is presenting additional data on the preclinical profile of ANA598 at the AASLD Meeting on Tuesday, November 4.

-- In a poster titled "In Vitro Studies Demonstrate that Combinations of Antiviral Agents that Include HCV Polymerase Inhibitor ANA598 have the Potential to Overcome Viral Resistance", Anadys will present the results of in vitro studies that show ANA598 to be synergistic with interferon-alpha, the protease inhibitor telaprevir (VX-950), and the nucleoside polymerase inhibitor PSI-6130 (the active agent of R7128). These studies also show that ANA598 retains activity against mutants known to confer resistance to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors and non-nucleosides that bind at the thumb site. Genotypic mutations resistant to ANA598 will be shown to be fully susceptible to interferon-alpha, telaprevir (VX-950) and PSI-6130. Data will also be presented demonstrating synergy between ANA598 and cytokines induced by ANA773, Anadys' TLR7 agonist oral prodrug, also in development for hepatitis C. These data strongly support the potential for ANA598 to be used in combination with multiple other agents approved or under investigation for hepatitis C.

-- In a poster titled "Antiviral Efficacy of the HCV RNA Polymerase Inhibitor ANA598 in the Chimpanzee Model of HCV Infection", Anadys will present data showing that ANA598 exhibits a substantial antivir
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
2. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
3. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
(Date:8/29/2014)... WEST JORDAN, Utah , Aug. 29, 2014 /PRNewswire/ ... Imaging Solutions, has acquired Polaris Medical Imaging, a leader ... CT scanners. This strategic acquisition allows BC Technical to ... their capabilities, specifically within MR and CT modalities. ... lower cost service," said Mark Alvarez , president ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4BC Technical Acquires Polaris Medical Imaging 2US CNS Disorders Drug Pipeline Insight 2014 2
... Reportlinker.com announces that a new market research ... Global Medical Laser Systems Industry ... This report analyzes the worldwide markets ... by the following Product Segments: Surgical Lasers, ...
... Reportlinker.com announces that a new market research ... Global Microscopes Industry ... report analyzes the worldwide markets for Microscopes ... Segments: Optical Microscopes, Charged Particle Microscopes, and ...
Cached Medicine Technology:Global Medical Laser Systems Industry 2Global Microscopes Industry 2
(Date:9/2/2014)... September 02, 2014 The Quantum ... Quantum Innovations, Inc . (QI), it has ... for MU2 Certification with a private IT security laboratory ... , The platform has Meaningful Use 1 certification status ... (7) approved and 15 pending patents. The accrediting organization ...
(Date:9/2/2014)... Kicking blog MichaelHusted.com is featuring an ... his role as a kicking coach, his kicking business, and ... to retired NFL kicker Michael Husted author of HustedKicking.com. , ... is one of the top pro free agent kickers out ... Anthony at our 2014 Pro Camp and I was impressed ...
(Date:9/2/2014)... 2 September 2014: The fact that mechanical heart valves ... by data from the ROPAC registry presented for the ... session by Professor Jolien W. Roos-Hesselink, co-chair with Professor ... found that 1.4% of pregnant women with a mechanical ... pregnancy. , The Registry Of Pregnancy And Cardiac disease ...
(Date:9/2/2014)... 02, 2014 “Harmonicas have been ... decade, primarily to help people with COPD or ... three developed systems,” says Dana Keller, PhD, co-inventor ... the goals are much the same – improved ... type of harmonica.” , The three approaches to ...
(Date:9/2/2014)... 2014 Fast hosting is a great ... compared many professional web hosting suppliers and announced that ... suppliers. , “It is hard to find a ... their competitors on hosting features, uptime, server speed and ... at affordable rates,” a manager of Top10BestSEOHosting.com says. , ...
Breaking Medicine News(10 mins):Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Top10BestSEOHosting.com Recommends Fast Web Hosting Suppliers 2
... and Manufacturing Plans Approved for Neuradiab(TM) Multi- center ... Clinical Trial ... TSX: ... the development and,commercialization of cancer therapies, today announced that it has received,notification from the ...
... June 3 When Brett Waslefsky,s wife,said her job ... a school,teacher, the stresses of the job, as well ... to stay healthy. With this casual,conversation, a new kind ... Employee Vita, a web-based vitamin company,that offers occupation specific ...
... childhood pneumococcal conjugate vaccine has been a boon in ... and the medical community must not get complacent, as ... rise, say scientists at a meeting today in Boston. ... the total burden of pneumococcal disease. It targets ...
... Cancer is the Number One Cause ... MAF Canine Cancer Campaign Seeking to Treat and Cure Dogs, DENVER, ... http://www.MorrisAnimalFoundation.org, a canine,cancer exclusive of special interest to dog owners ... the number one cause,of death in dogs over the age of two. ...
... To shed unwanted pounds,Americans, spend $46 billion ... and dietitians say merely choosing the right nutrient-dense,foods ... inflammation in our,bodies, and feel more energetic. But ... healthy ingredients we,re encouraged to buy. The article, ...
... asserts passage would strip illustrators of essential rights ... educational nonprofits, LAWRENCE, Kan., June 3 ... an international organization,representing highly trained professional medical illustrators ... Orphan Works Act,of 2008" (H.R. 5889/S. 2913), pending ...
Cached Medicine News:Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 2Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 3Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 4Health News:New Vitamin Company Caters to Occupational Health Concerns 2Health News:Despite vaccine, public should not get complacent about pneumococcal disease 2Health News:Canine Cancer Web Exclusive for Dog Owners and Lovers, Presented by Morris Animal Foundation - Features Colorado State and Cornell University Veterinary Cancer Experts 2Health News:Natural Solutions Names 45 Must-Have Foods for Healthy Weight Loss 2Health News:Association of Medical Illustrators Denounces 'Orphan Works' Bills Before Congress 2
... CONMED's family of products allows you to ... generators feature proprietary Energy Synchronous Processing Technology. ... current and voltage in all operational modes. ... to sample current and voltage over 450,000 ...
... achieves a secure clot, targeted to the ... hemostasis is needed, when control of bleeding ... and cautery, is ineffective or impractical., CROSSEAL* ... of human Biologically Active Component (BAC) and ...
GluStitch® is indicated for the closure of uncomplicated skin lacerations where there is little or no tissue loss....
... pacemaker family offers some ... automatic devices. Featuring the ... advanced technologies ever seen, ... incorporates the exclusive ventricular ...
Medicine Products: